Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are up during Friday’s premarket session as the company recently reported its fourth-quarter and full-year financial results, highlighting significant developments in its product pipeline.
Tonix Pharmaceuticals’ Sales Almost Doubled
Tonix Pharmaceuticals reported a fourth-quarter loss of $3.98, missing the consensus loss of $3.16. Sales reached $5.39 million, beating the consensus of $2.88 million.
Tonix Pharmaceuticals announced that since its launch in November 2025 through February 2026, more than 1,500 healthcare providers have prescribed Tonmya (cyclobenzaprine HCl sublingual tablets).
Approximately 2,500 patients have initiated treatment with the fibromyalgia drug, and cumulative prescriptions totaled approximately 4,200.
In August 2025, the U.S. FDA approved Tonmya for fibromyalgia in adults, making it the first new prescription medicine approved for this indication in more than 15 years.
The company is prioritizing expanding payer engagement and establishing contracts with commercial payers, while also progressing discussions with Medicare and Medicaid.
Cash Balance To Support Into Early 2027
The company also completed a $20 million registered direct offering with Point72 Asset Management to fund its commercialization efforts and pipeline development.
The company maintains a strong cash position, with approximately $207.6 million in cash and cash equivalents as of December 31, 2025, which it believes will support its operations into the first quarter of 2027.
Tonix Pharmaceuticals Technical Analysis
Currently, Tonix Pharmaceuticals is trading 5.2% below its 20-day simple moving average (SMA) and 18.7% below its 100-day SMA, indicating a bearish trend in the short to medium term.
Over the past 12 months, shares have decreased by 1.69% and are positioned closer to their 52-week lows than highs.
The RSI is at 36.03, which is considered neutral territory, while the MACD is at -0.6454, with the signal line at -0.6704, suggesting a bullish crossover as the MACD is above the signal line.
This combination indicates a potential for upward momentum in the near term.
- Key Resistance: $14.50
- Key Support: $12.80
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Tonix Pharmaceuticals Holding, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 10.4) — Stock is underperforming the broader market.
The Verdict: Tonix Pharmaceuticals Holding’s Benzinga Edge signal reveals a weak momentum score, indicating that the stock is currently underperforming relative to the market.
Investors should remain cautious as the company navigates its operational challenges and market conditions.
TNXP Stock Price Activity: Tonix Pharmaceuticals shares were up 1.12% at $13.56 during premarket trading on Friday, according to Benzinga Pro data.
Image by J Dennis via Shutterstock
Recent Comments